Mef E Nilbert

List of Publications by Year in Descending Order

96 papers	2,700 citations	29 h-index	48 g-index
104 ext. papers	3,069 ext. citations	3.8 avg, IF	4.71 L-index

#	Paper	IF	Citations
96	Medical and Nonmedical Information during Multidisciplinary Team Meetings in Cancer Care. *Current Oncology*, **2021**, 28, 1008-1016	2.8	1
95	Lynch syndrome-associated epithelial ovarian cancer and its immunological profile. *Gynecologic Oncology*, **2021**, 162, 686-693	4.9	1
94	Contributions to Multidisciplinary Team Meetings in Cancer Care: Predictors of Complete Case Information and Comprehensive Case Discussions. *Journal of Multidisciplinary Healthcare*, **2021**, 14, 2445-2452	2.8	1
93	Colorectal cancer in adolescents and young adults with Lynch syndrome: a Danish register-based study.. *BMJ Open*, **2021**, 11, e053538	3	
92	Health ProfessionalsRViews on Key Enabling Factors and Barriers of National Multidisciplinary Team Meetings in Cancer Care: A Qualitative Study. *Journal of Multidisciplinary Healthcare*, **2020**, 13, 179-186	2.8	7
91	Leadership perspectives in multidisciplinary team meetings; observational assessment based on the ATLAS instrument in cancer care. *Cancer Treatment and Research Communications*, **2020**, 25, 100231	2	4
90	New Pathogenic Germline Variants in Very Early Onset and Familial Colorectal Cancer Patients. *Frontiers in Genetics*, **2020**, 11, 566266	4.5	3
89	The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care. *Acta Oncologica*, **2020**, 59, 1343-1356	3.2	5
88	Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort. *BMC Cancer*, **2020**, 20, 345	4.8	3
87	Diagnostic spectrum and time intervals in SwedenRs first diagnostic center for patients with nonspecific symptoms of cancer. *Acta Oncologica*, **2019**, 58, 296-305	3.2	12
86	PatientsRand physiciansRdisagreement on patientsRunderstanding of clinical cancer trial information: a pairwise pilot study of mirroring subjective assessments compared with objective measurements. *Trials*, **2019**, 20, 301	2.8	3
85	Rational targeting of population groups and residential areas for colorectal cancer screening. *Cancer Epidemiology*, **2019**, 60, 23-30	2.8	7
84	Function, information, and contributions: An evaluation of national multidisciplinary team meetings for rare cancers. *Rare Tumors*, **2019**, 11, 2036361319841696	1.1	16
83	Risk of Synchronous and Metachronous Colorectal Cancer: Population-Based Estimates in Denmark with Focus on Non-Hereditary Cases Diagnosed After Age 50. *Scandinavian Journal of Surgery*, **2019**, 108, 152-158	3.1	5
82	Biallelic germline nonsense variant of MLH3 underlies polyposis predisposition. *Genetics in Medicine* , **2019**, 21, 1868-1873	8.1	23
81	Immunoprofiles of colorectal cancer from Lynch syndrome. *OncoImmunology*, **2019**, 8, e1515612	7.2	8
80	Risk of multiple colorectal cancer development depends on age and subgroup in individuals with hereditary predisposition. *Familial Cancer*, **2019**, 18, 183-191	3	1

79	Unsolicited information letters to increase awareness of Lynch syndrome and familial colorectal cancer: reactions and attitudes. *Familial Cancer*, **2019**, 18, 43-51	3	6
78	Benefits, barriers and opinions on multidisciplinary team meetings: a survey in Swedish cancer care. *BMC Health Services Research*, **2018**, 18, 249	2.9	40
77	Determinants of variable resource use for multidisciplinary team meetings in cancer care. *Acta Oncologica*, **2018**, 57, 675-680	3.2	12
76	Diagnostic pathway efficacy for urinary tract cancer: population-based outcome of standardized evaluation for macroscopic haematuria. *Scandinavian Journal of Urology*, **2018**, 52, 237-243	1.6	11
75	Molecular subtype classification of urothelial carcinoma in Lynch syndrome. *Molecular Oncology*, **2018**, 12, 1286-1295	7.9	15
74	Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types. *British Journal of Cancer*, **2017**, 117, 1702-1710	8.7	27
73	Genetic anticipation in Swedish Lynch syndrome families. *PLoS Genetics*, **2017**, 13, e1007012	6	9
72	Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X. *BMC Clinical Pathology*, **2017**, 17, 11	3	1
71	Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing. *Familial Cancer*, **2017**, 16, 195-203	3	40
70	Involvement of Chromatin Remodeling Genes and the Rho GTPases and in Ovarian Clear Cell Carcinoma. *Frontiers in Oncology*, **2017**, 7, 109	5.3	16
69	Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2. *Acta Oncologica*, **2016**, 55, 38-44	3.2	8
68	Fast-track access to urologic care for patients with macroscopic haematuria is efficient and cost-effective: results from a prospective intervention study. *British Journal of Cancer*, **2016**, 115, 770-5	8.7	9
67	Socioeconomic inequalities in breast cancer incidence and mortality in Europe-a systematic review and meta-analysis. *European Journal of Public Health*, **2016**, 26, 804-813	2.1	101
66	BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population. *Familial Cancer*, **2016**, 15, 507-12	3	8
65	Cutaneous malignant melanoma show geographic and socioeconomic disparities in stage at diagnosis and excess mortality. *Acta Oncologica*, **2016**, 55, 993-1000	3.2	19
64	No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families. *Familial Cancer*, **2016**, 15, 523-8	3	3
63	Patient representatives' views on patient information in clinical cancer trials. *BMC Health Services Research*, **2016**, 16, 36	2.9	5
62	Renal cell cancer linked to Lynch syndrome: Increased incidence and loss of mismatch repair protein expression. *International Journal of Urology*, **2016**, 23, 528-9	2.3	5

61	Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population. *Oncology Reports*, **2016**, 36, 2823-2835	3.5	25
60	Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. *BMC Urology*, **2016**, 16, 15	2.2	40
59	Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. *Urology*, **2015**, 86, 1212-7	1.6	55
58	Familial colorectal cancer type X: genetic profiles and phenotypic features. *Modern Pathology*, **2015** , 28, 30-6	9.8	31
57	Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival. *Translational Oncology*, **2015**, 8, 424-433	4.9	23
56	Multidisciplinary team conferences promote treatment according to guidelines in rectal cancer. *Acta Oncologica*, **2015**, 54, 447-53	3.2	36
55	Heterogenous mismatch-repair status in colorectal cancer. *Diagnostic Pathology*, **2014**, 9, 126	3	50
54	Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome. *Familial Cancer*, **2014**, 13, 537-45	3	11
53	Discovery-based protein expression profiling identifies distinct subgroups and pathways in leiomyosarcomas. *Molecular Cancer Research*, **2014**, 12, 1729-39	6.6	3
52	Functional implications of the p.Cys680Arg mutation in the MLH1 mismatch repair protein. *Molecular Genetics & Genomic Medicine*, **2014**, 2, 352-5	2.3	1
51	Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes. *PLoS ONE*, **2014**, 9, e107643	3.7	11
50	Gain of chromosomal region 20q and loss of 18 discriminates between Lynch syndrome and familial colorectal cancer. *European Journal of Cancer*, **2013**, 49, 1226-35	7.5	21
49	Mutation spectrum in South American Lynch syndrome families. *Hereditary Cancer in Clinical Practice*, **2013**, 11, 18	2.3	21
48	Distinct gene expression signatures in lynch syndrome and familial colorectal cancer type x. *PLoS ONE*, **2013**, 8, e71755	3.7	26
47	Functional characterization of MLH1 missense variants identified in Lynch syndrome patients. *Human Mutation*, **2012**, 33, 1647-55	4.7	17
46	Hereditary colorectal cancer diagnostics: morphological features of familial colorectal cancer type X versus Lynch syndrome. *Journal of Clinical Pathology*, **2012**, 65, 352-6	3.9	22
45	Challenges in the identification of MSH6-associated colorectal cancer: rectal location, less typical histology, and a subset with retained mismatch repair function. *American Journal of Surgical Pathology*, **2011**, 35, 1391-9	6.7	27
44	Bayesian modeling for genetic anticipation in presence of mutational heterogeneity: a case study in Lynch syndrome. *Biometrics*, **2011**, 67, 1627-37	1.8	5

43	Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. *Gynecologic Oncology*, **2011**, 121, 462-5	4.9	91
42	Deranged Wnt signaling is frequent in hereditary nonpolyposis colorectal cancer. *Familial Cancer*, **2011**, 10, 239-43	3	4
41	Interobserver variability in the evaluation of mismatch repair protein immunostaining. *Human Pathology*, **2010**, 41, 1387-96	3.7	45
40	Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. *Breast Cancer Research and Treatment*, **2010**, 120, 777-82	4.4	36
39	A review of statistical methods for testing genetic anticipation: looking for an answer in Lynch syndrome. *Genetic Epidemiology*, **2010**, 34, 756-68	2.6	24
38	A parametric model for analyzing anticipation in genetically predisposed families. *Statistical Applications in Genetics and Molecular Biology*, **2009**, 8, Article26	1.2	14
37	Role for genetic anticipation in Lynch syndrome. *Journal of Clinical Oncology*, **2009**, 27, 360-4	2.2	38
36	An effect from anticipation also in hereditary nonpolyposis colorectal cancer families without identified mutations. *Cancer Epidemiology*, **2009**, 33, 231-4	2.8	4
35	Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population. *Familial Cancer*, **2009**, 8, 75-83	3	30
34	Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrum. *Familial Cancer*, **2009**, 8, 209-13	3	44
33	Broad phenotypic spectrum in familial adenomatous polyposis; from early onset and severe phenotypes to late onset of attenuated polyposis with the first manifestation at age 72. *BMC Medical Genetics*, **2008**, 9, 101	2.1	12
32	Standardizing evaluation of sarcoma proliferation- higher Ki-67 expression in the tumor periphery than the center. *Apmis*, **2007**, 115, 707-12	3.4	9
31	Phenotypic heterogeneity in hereditary non-polyposis colorectal cancer: identical germline mutations associated with variable tumour morphology and immunohistochemical expression. *Journal of Clinical Pathology*, **2007**, 60, 781-6	3.9	9
30	Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. *Journal of the National Cancer Institute*, **2007**, 99, 291-9	9.7	174
29	The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. *Gynecologic Oncology*, **2006**, 101, 238-43	4.9	112
28	Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer?. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2004**, 444, 135-41	5.1	47
27	Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2004**, 445, 224-30	5.1	16
26	Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. *International Journal of Cancer*, **2004**, 111, 921-8	7.5	38

25	Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. *Cancer*, **2002**, 94, 2369-79	6.4	85
24	High frequency of microsatellite instability and loss of mismatch-repair protein expression in patients with double primary tumors of the endometrium and colorectum. *Cancer*, **2002**, 94, 2502-10	6.4	24
23	3 Applying tissue microarray in rectal cancer: Immunostaining of Ki-67 and p53. *Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas*, **2002**, 2, 149-157		
22	Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. *Archives of Pathology and Laboratory Medicine*, **2002**, 126, 702-5	5	78
21	High frequency of microsatellite instability and loss of mismatch-repair protein expression in patients with double primary tumors of the endometrium and colorectum **2002**, 94, 2502		1
20	. *Applied Immunohistochemistry & Molecular Morphology*, **2001**, 9, 358-363		22
19	Somatic frameshift alterations in mononucleotide repeat-containing genes in different tumor types from an HNPCC family with germline MSH2 mutation. *Genes Chromosomes and Cancer*, **2000**, 29, 33-9	5	28
18	A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain. *Genes Chromosomes and Cancer*, **1999**, 24, 207-12	5	20
17	hMLH1, hMSH2 and hMSH6 mutations in hereditary non-polyposis colorectal cancer families from southern Sweden. *International Journal of Cancer*, **1999**, 83, 197-202	7.5	23
16	Chemotherapy in Ewing□ sarcoma. *Acta Orthopaedica*, **1999**, 70, 69-73		10
15	Ewing□ sarcoma treatment in Scandinavia 1984-1990--ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV. *Acta Oncologica*, **1998**, 37, 375-8	3.2	37
14	Molecular and cytogenetics of soft tissue sarcomas. *Acta Orthopaedica*, **1997**, 273, 60-7		8
13	Pigmented villonodular synovitis. Monoclonality and metastasis--a case for neoplastic origin?. *Acta Orthopaedica*, **1995**, 66, 64-8		92
12	MDM2 gene amplification correlates with ring chromosome in soft tissue tumors. *Genes Chromosomes and Cancer*, **1994**, 9, 261-5	5	87
11	Independent origin of uterine leiomyomas with karyotypically identical alterations. *Gynecologic and Obstetric Investigation*, **1992**, 33, 246-8	2.5	17
10	Uterine leiomyoma cytogenetics. *Genes Chromosomes and Cancer*, **1990**, 2, 3-13	5	195
9	Chromosomal evolution and tumor progression in a myxoid liposarcoma. *Acta Orthopaedica*, **1990**, 61, 99-105		24
8	Trisomy 12 in uterine leiomyomas. A new cytogenetic subgroup. *Cancer Genetics and Cytogenetics*, **1990**, 45, 63-6		60

7	Chromosome rearrangements in two uterine sarcomas. *Cancer Genetics and Cytogenetics*, **1990**, 44, 27-35		34
6	Characteristic karyotypic anomalies identify subtypes of malignant fibrous histiocytoma. *Genes Chromosomes and Cancer*, **1989**, 1, 9-14	5	108
5	Complex karyotypic anomalies in a bizarre leiomyoma of the uterus. *Genes Chromosomes and Cancer*, **1989**, 1, 131-4	5	19
4	Different karyotypic abnormalities, t(1;6) and del(7), in two uterine leiomyomas from the same patient. *Cancer Genetics and Cytogenetics*, **1989**, 42, 51-3		32
3	Cytogenetic abnormalities in an angioleiomyoma. *Cancer Genetics and Cytogenetics*, **1989**, 37, 61-4		16
2	No amplification or rearrangement of INT1, GLI, or COL2A1 in uterine leiomyomas with t(12;14)(q14-15;q23-24). *Cancer Genetics and Cytogenetics*, **1989**, 39, 195-201		25
1	Ring formation and structural rearrangements of chromosome 1 as secondary changes in uterine leiomyomas with t(12;14)(q14-15;q23-24). *Cancer Genetics and Cytogenetics*, **1988**, 36, 183-90		48